Promising Phase 1b Results for invIOs's APN401 Cell Therapy in Advanced Tumors

invIOs GmbH has completed a Phase 1b trial for its novel cell therapy, APN401, targeting advanced solid tumors. The therapy, employing autologous cells and the EPiC platform, modifies patient cells to enhance cancer-fighting capabilities. The trial included 11 patients with various cancers, such as head and neck, colorectal, and small cell lung cancer.

Results showed a favorable safety profile and a 37.5% disease stabilization rate. Despite modest tumor responses, the median overall survival of 7.8 months in a heavily pretreated group was significant. These findings suggest the potential of APN401 in treating patients with limited options.

invIOs plans to advance its pipeline, including INV441 for glioblastoma, building on APN401's success.